N/A N=162 Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.
Burn Injuries
Primary: Time to Healing — 16; 17 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Leukemia
Primary: Recommended Phase II Dose (RP2D) of Bendamustine — 120 mg/m^2
Phase 2 N=95 Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
Hepatitis C
Primary: Percentage of Participants Achieving RVR — 5.6; 75.0; 78.9; 68.8 Percentage of Participants — p=<0.001
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
Phase 2 N=494 Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment — 0.03; -0.58; -0.75 percentage of HbA1c — p=<0.0001
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
Phase 2 N=12 Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
N/A N=33 The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Phase 3 N=195 Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
Breast Cancer · Vaginal Dryness
Primary: Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics — 63.6; 55.8; 66.0 units on a scale — p=0.1675
Phase 3 N=899 Study of 0417 Ointment in the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 123; 130; 86 participants
N/A N=15 Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease
Diffuse Parenchymal Lung Disease · Pulmonary Hypertension
Primary: Change in Diffusion Capacity Measured at Baseline and One Hour. — -0.26 ml/min/mmHg — p==0.30
N/A N=39 Bupivacaine Versus Ropivacaine on Diaphragmatic Motility and Ventilatory Function
Paresis
Primary: Forced Expiratory Volume at 1 Second (% Change From Baseline) — -22.4; -29.4 percentage of change from baseline
Phase 3 N=121 Heart Rate Reduction in Heart Failure
Heart Failure
Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters
Phase 4 N=60 Post Market Clinical Follow-up Study
Hip or Knee Surgery
Primary: Minimize the Risk of the Development of Blistering. — 60 participants
Phase 3 N=2,067 An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Rheumatoid Arthritis
Primary: Percentage of Participants With ≥ 1 Adverse Event — 96.3 Percentage of participants